Year: 2026
Type: article
Abstract: α-cells exhibit heterogeneity in their hormone production, whereby distinct α-cell subpopulations can be induced to produce active glucagon-like peptide-1 (GLP-1). However, the mechanisms that govern α-cell GLP-1 production remain poorly defined and whether these differ between sex is unknown. We previously identified 14-3-3-ζ as an indirect negative regulator of α-cell GLP-1 production in vitro. Therefore, we tested the hypothesis that β-cell 14-3-3-ζ ablation exerts sex-dependent protection against metabolic disease through alteration of the α-cell endocrine profile. Male and female mice with targeted manipulation of GLP-1 production in α-cells and 14-3-3-ζ expression in β-cells were studied. Further, publicly available human pancreas data were analyzed to identify sex-dependent differences in islet cell populations. Loss of α-cell-derived GLP-1 impaired β-cell compensation in response to high-fat diet-induced metabolic stress, and β-cell 14-3-3-ζ ablation improved glucose tolerance during a mixed-meal tolerance test in male, but not female, mice. Conversely, overexpression of 14-3-3-ζ blunted the effect of a GLP-1 receptor agonist to promote insulin secretion in male, but not female, mice. Further, β-cell 14-3-3-ζ ablation increased α-cell abundance in male mice while enhancing α-cell GLP-1 production and secretion in both sexes. Finally, α-cell numbers were higher in females compared to males in both mouse and human islets, and α-cell GLP-1 production was higher in females compared to male mice. Together, these findings identify β-cell 14-3-3-ζ as an upstream constraint on α-cell GLP-1 production and reveal sex-dependent regulation of α-cell abundance, establishing β-cell 14-3-3-ζ and biological sex as key determinants of α-cell GLP-1 production.
Source: Endocrinology
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,750
Funders: Hartwell Foundation, Department of Food Science and Technology, University of California, Davis, Stanford Diabetes Research Center, Norges Idrettshøgskole, National Institutes of Health, University of California, Davis, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: Defining alpha-cell proglucagon processing for type 2 diabetes treatment, Human Pancreas Analysis Program-T2D, G3780977336, Penn integrated Human Pancreas procurement and Analysis Program, Integrated Program for Human Pancreas Procurement and Analysis, A novel role for 14-3-3-ζ in regulating islet cell crosstalk, G9000000146, G9000138463, G9000842607, G9000843012, G9000843988, 14-3-3-zeta regulation of islet health, Stanford Diabetes Research Center, Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D), Training Program in Pharmacology
OpenAlex ID: W7171377520
FWCI:
Cites:
Cited by:
Related to:
